Literature DB >> 26055341

MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.

Z Sun1, N Zhou1, Q Han2, L Zhao1, C Bai1, Y Chen3, J Zhou4, R C Zhao5,6.   

Abstract

PURPOSE: The response rate of first-line fluoropyrimidine-based regimens for metastatic colorectal cancer (mCRC) is generally less than 50 %. The down-regulation of miR-197 in colorectal cancer cells after exposure to 5-fluorouracil might be related to the mechanism of resistance to fluoropyrimidine-based chemotherapy. So we investigated the regulatory mechanism of miR-197 on 5-FU sensitivity.
METHODS: Dual luciferase reporter gene construct and dual luciferase reporter assay were used to identify the target of miR-197. TYMS expression was evaluated by immunohistochemistry staining. 5-Fu resistance of colorectal cancer cell lines was detected by MTS assay. The expression of miR-197 was detected by real time PCR.
RESULTS: A luciferase assay and western blot analysis confirmed that miR-197 directly binds to and negatively regulates TYMS expression. Overexpressing miR-197 could increase the sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU). The expression of miR-197 negatively correlated with TYMS expression in cancerous tissues from patients with stage IV colorectal cancer.
CONCLUSION: miR-197 mediates the response of colorectal cancer cells to 5-FU by regulating TYMS expression.

Entities:  

Keywords:  5-Fluorouracil; Colorectal cancer; Resistance; Thymidylate synthase; miR-197

Mesh:

Substances:

Year:  2015        PMID: 26055341     DOI: 10.1007/s12094-015-1318-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

1.  Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer.

Authors:  Rong Shen; Hongliang Liu; Juyi Wen; Zhensheng Liu; Li-E Wang; Qiming Wang; Dongfeng Tan; Jaffer A Ajani; Qingyi Wei
Journal:  Mol Carcinog       Date:  2014-04-23       Impact factor: 4.784

2.  MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance.

Authors:  Yuemeng Dai; Cheng-Hui Xie; John P Neis; Chun-Yang Fan; Emre Vural; Paul M Spring
Journal:  Head Neck       Date:  2010-11-29       Impact factor: 3.147

3.  Implications of microRNA-197 downregulated expression in esophageal cancer with poor prognosis.

Authors:  T-Y Wang; S-G Liu; B-S Zhao; B Qi; X-G Qin; W-J Yao
Journal:  Genet Mol Res       Date:  2014-07-25

4.  MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression.

Authors:  L Scapoli; A Palmieri; L Lo Muzio; F Pezzetti; C Rubini; A Girardi; F Farinella; M Mazzotta; F Carinci
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Oct-Dec       Impact factor: 3.219

5.  Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA.

Authors:  N Dai; Z Y Zhong; Y P Cun; Y Qing; Ch Chen; P Jiang; M X Li; D Wang
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

6.  5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.

Authors:  Jianfeng Zhou; Yanping Zhou; Bin Yin; Wei Hao; Lin Zhao; Wenyi Ju; Chunmei Bai
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

7.  Identification of differentially expressed microRNAs in human male breast cancer.

Authors:  Ulrich Lehmann; Thomas Streichert; Benjamin Otto; Cord Albat; Britta Hasemeier; Henriette Christgen; Elisa Schipper; Ursula Hille; Hans H Kreipe; Florian Länger
Journal:  BMC Cancer       Date:  2010-03-23       Impact factor: 4.430

8.  Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo.

Authors:  Jinxia He; Ganfeng Xie; Jingtao Tong; Yonghai Peng; Haihui Huang; Jianjun Li; Ning Wang; Houjie Liang
Journal:  Cell Biochem Biophys       Date:  2014-11       Impact factor: 2.194

9.  Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies.

Authors:  Li-Xin Qiu; Qi-Yun Tang; Jian-Ling Bai; Xiao-Ping Qian; Ru-Tian Li; Bao-Rui Liu; Ming-Hua Zheng
Journal:  Int J Cancer       Date:  2008-11-15       Impact factor: 7.396

10.  MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.

Authors:  Jingli Shang; Fu Yang; Yuzhao Wang; Yue Wang; Geng Xue; Qian Mei; Fang Wang; Shuhan Sun
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

View more
  16 in total

1.  Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis.

Authors:  Jianchang Wei; Ping Yang; Wanglin Li; Feng He; Shanqi Zeng; Tong Zhang; Junbin Zhong; Di Huang; Zhuanpeng Chen; Chengxing Wang; Huacui Chen; He Hu; Jie Cao
Journal:  Exp Ther Med       Date:  2017-01-02       Impact factor: 2.447

Review 2.  Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.

Authors:  Francesco Prete; MariaTeresa Rotelli; Alessandro Stella; Giovanna Calculli; Lucia Ilaria Sgaramella; Antonio Amati; Nicoletta Resta; Mario Testini; Angela Gurrado
Journal:  Clin Exp Med       Date:  2022-08-01       Impact factor: 5.057

Review 3.  MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Authors:  Fahima Danesh Pouya; Maria Gazouli; Yousef Rasmi; Dimitra Ioanna Lampropoulou; Mohadeseh Nemati
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

4.  miR-197-3p reduces epithelial-mesenchymal transition by targeting ABCA7 in ovarian cancer cells.

Authors:  Weiquan Xie; Chengyu Shui; Xiping Fang; Yuqiu Peng; Li Qin
Journal:  3 Biotech       Date:  2020-08-04       Impact factor: 2.406

5.  miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.

Authors:  Suna Zhou; Wenguang Ye; Yanjun Zhang; Dequan Yu; Qiuju Shao; Jun Liang; Mingxin Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

6.  MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase.

Authors:  Weidong Xu; Huayong Jiang; Fuli Zhang; Junmao Gao; Jun Hou
Journal:  Oncol Lett       Date:  2017-03-23       Impact factor: 2.967

Review 7.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets.

Authors:  Pooneh Mokarram; Mohammed Albokashy; Maryam Zarghooni; Mohammad Amin Moosavi; Zahra Sepehri; Qi Min Chen; Andrzej Hudecki; Aliyeh Sargazi; Javad Alizadeh; Adel Rezaei Moghadam; Mohammad Hashemi; Hesam Movassagh; Thomas Klonisch; Ali Akbar Owji; Marek J Łos; Saeid Ghavami
Journal:  Autophagy       Date:  2017-02-23       Impact factor: 16.016

Review 8.  Kangai Injection, a Traditional Chinese Medicine, Improves Efficacy and Reduces Toxicity of Chemotherapy in Advanced Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Siqi Huang; Weijun Peng; Dan Mao; Shaofan Zhang; PanPan Xu; PengJi Yi; Sifang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-15       Impact factor: 2.629

9.  MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.

Authors:  Fei Xu; Ming-Liang Ye; Yu-Peng Zhang; Wen-Jie Li; Meng-Ting Li; Hai-Zhou Wang; Xiao Qiu; Yan Xu; Jin-Wen Yin; Qian Hu; Wan-Hui Wei; Ying Chang; Lan Liu; Qiu Zhao
Journal:  Cancer Sci       Date:  2020-03-14       Impact factor: 6.716

10.  Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.

Authors:  Jeong Mi Yang; Ji-Young Jang; Yoon Kyung Jeon; Jin Ho Paik
Journal:  J Transl Med       Date:  2018-06-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.